Dr Jan Schmidt-Brand
Chief Executive Officer and Chief Financial Officer
Dr Jan Schmidt-Brand has been Chief Executive Officer of Heidelberg Pharma AG since 2014 and Chief Financial Officer since 2012. Until the acquisition by WILEX AG (former name of the Company), Dr Schmidt-Brand held the position of CEO/CFO in the former Heidelberg Pharma GmbH. The doctor of law has over 30 years’ experience in leading positions in the commercial as well as the fiscal sector of pharmaceutical companies. From 1997 to 2001 he was Managing Director of EBEWE Arzneimittel GmbH, an Austrian BASF Pharma subsidiary. Prior to this, he held several positions at the BASF Group for a total of eight years, most recently as an executive in the central tax department with a general commercial power of attorney (“Prokurist”). Dr Jan Schmidt-Brand studied law, business management and French at the universities of Bayreuth and Geneva and obtained his doctoral degree from the University of Mannheim. He was member of the board of directors of BIO Deutschland e.V. until 2019.
Prof Dr Andreas Pahl
Chief Scientific Officer
Professor Andreas Pahl has been appointed to serve as Chief Scientific Officer of Heidelberg Pharma AG on June 2, 2016. Professor Pahl has worked as Chief Scientific Officer and member of the executive management of the subsidiary Heidelberg Pharma Research GmbH since September 2012 and can look back on 20 years’ experience in research and higher education. Prior to his position at Heidelberg Pharma, he spent four years as Head of Late Pharmacology at Nycomed and Takeda Pharmaceuticals. After graduating in chemistry from the University of Berlin, he spent several years lecturing at TU Berlin and the University of Erlangen-Nuremberg (FAU), at which he was also appointed Professor of Pharmacology and Toxicology. He will continue to perform his teaching duties at FAU. Professor Pahl is member of the Supervisory Board of Emergence Therapeutics AG.